|
Title
|
Publication Date
|
Price
|
Relevance
|
Commercial Insight: Antihypertensives
New challenges for a maturing market
|
Sep 2006 |
£8,365 |
100% |
Personalized Medicine Partnering Terms and Agreements
3rd Edition
|
Feb 2012 |
£3,160 |
92% |
The Cardiovascular Market Outlook to 2016
Healthcare
|
Jun 2011 |
£2,425 |
88% |
Systems Biology
A Disruptive Technology
|
May 2008 |
£710 |
86% |
GPCRs in Drug Discovery
Efforts to De-Orphanize Novel Gpcr Targets Are Increasing
|
Nov 2011 |
£2,215 |
85% |
|
Commercializing Biomarkers in Therapeutic and Diagnostic Applications
|
May 2011 |
£2,020 |
83% |
Pharmacogenomics Partnering Terms and Agreements
3rd Edition
|
Feb 2012 |
£1,705 |
81% |
|
Biomarker Partnering Terms and Agreements
|
Feb 2012 |
£1,705 |
80% |
Companion Diagnostics Partnering Terms and Agreements
3rd Edition
|
Feb 2012 |
£1,705 |
79% |
Diagnostics Partnering Terms and Agreements
3rd Edition
|
Feb 2012 |
£1,705 |
79% |
Stakeholder Opinions: Hemophilia
The harsh reality of commercialising a great research opportunity?
|
Jun 2010 |
£2,405 |
79% |
Clinical Stage Partnering Terms and Agreements in Pharma and Biotech
2nd edition
|
Apr 2010 |
£1,705 |
79% |
Stakeholder Opinion: Erectile Dysfunction
Identifying product differentiation and patient segmentation strategies
|
Dec 2006 |
£2,400 |
75% |
Manufacturing & Supply Agreements in Pharma, Biotech and Diagnostics
3rd Edition
|
Oct 2010 |
£1,705 |
74% |
Co-promotion and Co-marketing Agreements in Pharma, Biotech and diagnostics
5th Edition
|
Jul 2011 |
£1,895 |
71% |
|
New Drug Futures 2009
|
Jan 2012 |
£1,995 |
71% |
Commercial and Pipeline Perspectives: Obesity
Lack of Reimbursement Limits Market Potential
|
Dec 2006 |
£7,210 |
70% |
|
Partnering Agreements with Abbott
|
Sep 2011 |
£630 |
70% |
|
Bioinformatics Partnering Agreements
|
Nov 2011 |
£1,705 |
69% |
|
Vaccine Partnering Terms and Agreements
|
Nov 2011 |
£1,705 |
68% |
|
Monoclonal Antibodies Report
|
Jun 2008 |
£4,805 |
64% |
Outlook for RNAi, 2007
siRNA and miRNA in biology, diagnostics and therapeutics
|
Jun 2007 |
£1,820 |
63% |
Reformulation Strategies
Comparisons of Past and Future Reformulation Strategies
|
Sep 2006 |
£4,805 |
62% |
|
Antiageing and Life Enhancement Pharmacotherapeutics
|
Jan 2006 |
£795 |
62% |
Distribution Stage Partnering Terms and Agreements in Pharma and Biotech
3rd edition
|
Oct 2010 |
£1,705 |
61% |
|
Innovations in Protein Kinase Therapies: Company pipelines, therapeutic applications and market forecasts
|
May 2009 |
£2,425 |
61% |
Drug Delivery Partnering Terms and Agreements in Pharma and Biotech
2nd Edition
|
Nov 2010 |
£1,705 |
61% |
Discovery Stage Partnering Terms and Agreements in Pharma and Biotech
2nd edition
|
Jun 2010 |
£1,705 |
60% |
Advanced Oral & Parenteral Drug Delivery Technologies
Players, Products & Prospects to 2015
|
Jan 2011 |
£995 |
60% |
|
Pre-clinical Stage Partnering Terms and Agreements in Pharma, Biotech and Diagnostics
|
Jun 2010 |
£1,705 |
57% |
